4.[20220824]Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney …
페이지 정보
작성자 신호식 작성일23-02-03 12:29 조회467회 댓글0건관련링크
-
https://youtu.be/C6Z0u4nDDE0
431회 연결
https://youtu.be/C6Z0u4nDDE0
본문
학문적 목적으로만 첨부한 자료를 사용해 주시길 부탁드립니다
Multicenter Study Transplantation
. 2022 Sep 1;106(9):e404-e412. doi: 10.1097/TP.0000000000004228. Epub 2022 Jun 30.
The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients
Jeong-Hoon Lim 1, Soie Kwon 2, Yena Jeon 3, Young Hoon Kim 4, Hyunwook Kwon 4, Yon Su Kim 2, Hajeong Lee 2, Yong-Lim Kim 1, Chan-Duck Kim 1, Sun-Hee Park 1, Jong Soo Lee 5, Kyung Don Yoo 5, Hyung Eun Son 6, Jong Cheol Jeong 6, Jeonghwan Lee 7, Jung Pyo Lee 7, Jang-Hee Cho 1
Affiliations expand
PMID: 35768908 DOI: 10.1097/TP.0000000000004228
Abstract
Background: The efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) have not been investigated in kidney transplant recipients (KTRs) with diabetes. We evaluated the impact of SGLT2i in a multicenter cohort of diabetic KTRs.
Methods: A total of 2083 KTRs with diabetes were enrolled from 6 transplant centers in Korea. Among them, 226 (10.8%) patients were prescribed SGLT2i for >90 d. The primary outcome was a composite outcome of all-cause mortality, death-censored graft failure (DCGF), and serum creatinine doubling. An acute dip in estimated glomerular filtration rate (eGFR) over 10% was surveyed after SGLT2i use.
Results: During the mean follow-up of 62.9 ± 42.2 mo, the SGLT2i group had a lower risk of primary composite outcome than the control group in the multivariate and propensity score-matched models (adjusted hazard ratio, 0.43; 95% confidence interval, 0.24-0.78; P = 0.006 and adjusted hazard ratio, 0.45; 95% confidence interval, 0.24-0.85; P = 0.013, respectively). Multivariate analyses consistently showed a decreased risk of DCGF and serum creatinine doubling in the SGLT2i group. The overall eGFR remained stable without the initial dip after SGLT2i use. A minority (15.6%) of the SGLT2i users showed acute eGFR dip during the first month, but the eGFR recovered thereafter. The risk factors for the eGFR dip were time from transplantation to SGLT2i usage and mean tacrolimus trough level.
Conclusions: SGLT2i improved a composite of all-cause mortality, DCGF, or serum creatinine doubling in KTRs. SGLT2i can be used safely and have beneficial effects on preserving graft function in diabetic KTRs.
Multicenter Study Transplantation
. 2022 Sep 1;106(9):e404-e412. doi: 10.1097/TP.0000000000004228. Epub 2022 Jun 30.
The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients
Jeong-Hoon Lim 1, Soie Kwon 2, Yena Jeon 3, Young Hoon Kim 4, Hyunwook Kwon 4, Yon Su Kim 2, Hajeong Lee 2, Yong-Lim Kim 1, Chan-Duck Kim 1, Sun-Hee Park 1, Jong Soo Lee 5, Kyung Don Yoo 5, Hyung Eun Son 6, Jong Cheol Jeong 6, Jeonghwan Lee 7, Jung Pyo Lee 7, Jang-Hee Cho 1
Affiliations expand
PMID: 35768908 DOI: 10.1097/TP.0000000000004228
Abstract
Background: The efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) have not been investigated in kidney transplant recipients (KTRs) with diabetes. We evaluated the impact of SGLT2i in a multicenter cohort of diabetic KTRs.
Methods: A total of 2083 KTRs with diabetes were enrolled from 6 transplant centers in Korea. Among them, 226 (10.8%) patients were prescribed SGLT2i for >90 d. The primary outcome was a composite outcome of all-cause mortality, death-censored graft failure (DCGF), and serum creatinine doubling. An acute dip in estimated glomerular filtration rate (eGFR) over 10% was surveyed after SGLT2i use.
Results: During the mean follow-up of 62.9 ± 42.2 mo, the SGLT2i group had a lower risk of primary composite outcome than the control group in the multivariate and propensity score-matched models (adjusted hazard ratio, 0.43; 95% confidence interval, 0.24-0.78; P = 0.006 and adjusted hazard ratio, 0.45; 95% confidence interval, 0.24-0.85; P = 0.013, respectively). Multivariate analyses consistently showed a decreased risk of DCGF and serum creatinine doubling in the SGLT2i group. The overall eGFR remained stable without the initial dip after SGLT2i use. A minority (15.6%) of the SGLT2i users showed acute eGFR dip during the first month, but the eGFR recovered thereafter. The risk factors for the eGFR dip were time from transplantation to SGLT2i usage and mean tacrolimus trough level.
Conclusions: SGLT2i improved a composite of all-cause mortality, DCGF, or serum creatinine doubling in KTRs. SGLT2i can be used safely and have beneficial effects on preserving graft function in diabetic KTRs.
